BABjörn Andréasson

Björn Andréasson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Björn Andréasson has a total of 333 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study

    by Anneli Enblom Larsson, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander

    Introduction: The management to reduce risk of thromboembolic complications in polycythemia vera and essential thrombocythemia are well established, but for other conditions with elevated hemoglobin, hematocrit, or platelets there are no consensus regarding treatment and follow up.Aims: To assess frequency of elevated blood values in patients with thromboembolic event, how many of these should be investigated further regarding myeloproliferative neoplasm and if the risk of recurrent event is depending on underlying condition.Methods: Retrospective cohort study of 3931 adult patients in the county of Norrbotten, Sweden, with thromboembolism during 2017 and 2018.Results: Of the 3931 patients, 1195 had either elevated Hb, HCT, or platelets fulfilling the 2016 revised WHO criteria for PV and ET, and out of these 411 should be evaluated regarding underlying myeloproliferative neoplasms. Unexplained thrombocytosis and secondary erythrocytosis were associated with the highest rate of recurrent event as well as the most inferior restricted mean survival time.Conclusion: Elevated blood values are common in patients with thromboembolic event and the high risk of recurrent event and inferior restricted mean survival time in patients with unexplained thrombocytosis and secondary erythrocytosis implicates the importance of finding and managing the underlying condition.


  • Open Access

    Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

    by Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste Op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, et al.

    Background: Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called minimal residual disease, has been shown to be prognostic for progression-free and overall survival. However, for multiple myeloma, it is unclear whether patients attaining minimal residual disease negativity may be candidates for treatment discontinuation. We investigated, if longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD) may predict disease progression earlier and with higher sensitivity compared to biochemical assessments. Methods: Patients from the Nordic countries with newly diagnosed multiple myeloma enrolled in the European-Myeloma-Network-02/Hovon-95 (EMN02/HO95) trial and undergoing bone marrow aspiration confirmation of complete response, were eligible for this Nordic Myeloma Study Group (NMSG) substudy. Longitdudinal flow-MRD assessment of bone marrow samples was performed to identify and enumerate residual malignant plasma cells until observed clinical progression. Results: Minimal residual disease dynamics were compared to biochemically assessed changes in serum free light chain and M-component. Among 20 patients, reaching complete response or stringent complete response during the observation period, and with ≥3 sequential flow-MRD assessments analysed over time, increasing levels of minimal residual disease in the bone marrow were observed in six cases, preceding biochemically assessed disease and clinical progression by 5.5 months and 12.6 months (mean values), respectively. Mean malignant plasma cells doubling time for the six patients was 1.8 months (95% CI, 1.4–2.3 months). Minimal malignant plasma cells detection limit was 4 × 10–5. Conclusions: Flow-MRD is a sensitive method for longitudinal monitoring of minimal residual disease dynamics in multiple myeloma patients in complete response. Increasing minimal residual disease levels precedes biochemically assessed changes and is an early indicator of subsequent clinical progression. Trial registration: NCT01208766


  • Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation

    by Sigrun Einarsdottir, Malin Nicklasson, Malin Veje, Tomas Bergström, Marie Studahl, Mikael Lisak, Mikael Olsson, Berit Johansson, Björn Andreasson, Bénédicte Piauger, et al.


  • ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO‐defined polycythaemia vera patients

    by Björn Andréasson, Helna Pettersson, Carina Wasslavik, Peter Johansson, Lars Palmqvist, Julia Asp

    Polycythaemia vera (PV) patients have an overall comparatively favourable prognosis, but disease progression is very heterogeneous and life‐threatening thrombosis and bleedings are frequent complications in untreated disease. Moreover, transformation to more severe secondary myelofibrosis and acute myeloid leukaemia can occur. The aim of this study was to identify gene mutations that could be used together with clinical data as prognostic markers to guide treatment decisions in PV patients. A well‐characterized WHO‐defined cohort of PV patients was used. Clinical data and blood values were evaluated and a myeloid sequencing panel was used to screen for additional mutations other than the diagnostic JAK2 V617F and JAK2 exon 12 mutations. In 78% of the PV patients, at least one mutation additional to JAK2 V617F was detected. Additional mutations in genes coding for epigenetic modifiers, like TET2, DNMT3A and ASXL1, were most frequent. When correlated to overall survival, mutations in ASXL1 were significantly associated with inferior survival. In an attempt to obtain prognostic guidance in a larger number of patients, the presence of ASXL1 mutations was combined with age and vascular complications prior to diagnosis. Based on these data we were able to define three risk groups that predicted survival.


  • Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up

    by Erik Ahlstrand, Jan Samuelsson, Marie Lindgren, Helna Pettersson, Maria Liljeholm, Anna Ravn‐Landtblom, Stefan Scheding, Björn Andréasson

    Objective: To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV).Methods: Nested case‐control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared with matched controls.Results: Incidence of vascular complications was 2.0 and 3.4 events per 100 patient‐years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with anti‐thrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared with controls.Conclusions: The risk of vascular complications is high in both ET and PV, and these complications have a considerable impact on life expectancy. The protective effect of anti‐thrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment.


  • Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

    by Gunnar Birgegard, Jan Samuelsson, Erik Ahlstrand, Elisabeth Ejerblad, Christian Enevold, Waleed Ghanima, Hans Hasselbalch, Claus H. Nielsen, Håvar Knutsen, Ole B. Pedersen, et al.

    Objectives: The study investigates the hypothesis that inflammation in myelofibrosis (MF) like in myeloma and lymphoma, may disturb iron distribution and contribute to anaemia.Methods: A cross‐sectional study of 80 MF and 23 ET patients was performed.Results: About 35% of anaemic MF patients had functional iron deficiency (FID) with transferrin saturation P = 0.03). Hepcidin was significantly higher in MF patients with anaemia, including transfusion‐dependent patients, 50.6 vs 24.4 µg/L (P = 0.01). There was a significant negative correlation between Hb and inflammatory markers in all MF patients: IL‐2, IL‐6 and TNF‐α, (P < 0.01‐0.03), LD (P = 0.004) and hepcidin (P = 0.03). These correlations were also seen in the subgroup of anaemic MF patients (Table ). Tsat correlated negatively with CRP (P < 0.001). Symptom burden was heavier in MF patients with FID, and MPN‐SAF quality of life scores correlated with IL‐6 and CRP.Conclusions: The inflammatory state of MF disturbs iron turnover, FID is common and contributes to anaemia development and impairment of QoL. Anaemic MF patients should be screened for FID.


  • Genetic variation in IL28B (IFNL3) and response to interferon‐alpha treatment in myeloproliferative neoplasms

    by Marie Lindgren, Jan Samuelsson, Lars Nilsson, Håvar Knutsen, Waleed Ghanima, Johan Westin, Peter L. Johansson, Björn Andréasson

    Objective: In myeloproliferative neoplasms (MPN), interferon‐alpha (IFN‐α) is an effective treatment with disease‐modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the IL28B (IFNL3) gene in response to IFN‐α treatment. In this study, we sought to evaluate the prognostic impact of IL28B rs12979860, rs8099917, and rs12980275 on IFN‐α treatment response in myeloproliferative neoplasms.Method: We retrospectively evaluated 100 patients with MPN treated with IFN‐α. The hematologic treatment response on IFN‐α was compared between patients and correlated with host genetic variations in IL28B. The genotypes of IL28B were determined by allelic discrimination assays.Results: The CC genotype of rs12979860 was found significantly associated with hematologic response in polycythemia vera (PV) with a complete response (CR) in 79% (CC) compared to 48% (non‐CC), (P = .036). No association between the genotypes and treatment response on hydroxyurea was found.Conclusion: These results imply an effect of IL28B genotype on the outcome of IFN‐α treatment in MPN.


  • Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real‐world data from the Swedish MPN Registry

    by Khadija Abdulkarim, Jan Samuelsson, Peter Johansson, Björn Andréasson

    Objective: The study mainly aimed at investigating possible correlations between peripheral blood counts, erythropoietin (EPO), JAK2 V617F mutation, and vascular complications prior to diagnosis of a population‐based cohort of newly diagnosed patients with myeloproliferative neoplasms (MPN).Method: The study comprises 1105 patients with polycythemia vera (PV) and 1284 patients with essential thrombocythemia (ET) registered in the Swedish MPN Registry.Results: Vascular complications, prior to diagnosis, were registered in 37% of PV patients. In multivariate analysis, low hemoglobin was the only significant risk factor (P=.0120). Among ET patients, 35% had encountered a vascular complication. Risk factors for thromboembolic complications in ET were identified as age>65 years, white cell count>12×109/L, and the presence of JAK2 V617F mutation (P=.0004, P=.0038, and P=.0016, respectively). A JAK2 V617F mutation was present in 71% of ET patients with vascular complications, compared to 60% in patients without. A majority of complications were thromboembolic, in both PV and ET.Conclusion: We conclude that vascular complications among newly diagnosed patients had affected more than one‐third of our study population. Risk factors for vascular complications prior to diagnosis were lower hemoglobin in PV, and the presence of JAK2 V617F mutation, higher age, and leukocytosis in ET.


  • Open Access

    Issue Information – TOC – Masthead

    by Aaron T. Gerds, William F. Pirl, Inga T. Lennes, Sophia C. Kamran, Amy Berrington de González, Andrea K. Ng, Daphne A. Haas‐Kogan, Akila N. Viswanathan, Linda X. Yin, Patrick K. Ha, et al.

  • High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms

    by Anneli Enblom, Emma Lindskog, Hans Hasselbalch, Ditte Hersby, Marie Bak, Jennifer Tetu, François Girodon, Björn Andréasson